Response of thymoma to cetuximab

Farina, Gabriella; Garassino, Marina Chiara; Gambacorta, Marcello; Verde, Nicla La; Gherardi, Giorgio; Scanni, A.

doi:10.1016/s1470-2045(07)70141-9

Cited by 71 publications

(43 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…90 The rarity of epidermal growth factor receptor (EGFR) mutations in thymic tumors explains why responses to EGFR inhibitors had been rarely observed. 91 One Phase II trial with gefi tinib was conducted in chemorefractory tumors.…”

Section: Targeted Therapiesmentioning

confidence: 99%

See 1 more Smart Citation

Thymoma and thymic carcinoma

Venuta

Rendina

Anile

et al. 2012

Gen Thorac Cardiovasc Surg

View full text Add to dashboard Cite

Thymic tumors comprise a heterogeneous group of neoplasms with a wide spectrum of clinical presentations. The evolution of the disease is often unpredictable, ranging from an indolent attitude to the possibility of intra- and extrathoracic spread. From the histological point of view, thymoma and thymic carcinoma are the most frequent subtypes and arise only from thymic epithelial cells. Other histological types are even more rare and are usually considered separately. A number of prognostic factors have been validated as predictors of outcome: staging, World Health Organization histological classification, diameter of the tumor, associated paraneoplastic syndromes, completeness of resection, and early onset of recurrence. Complete surgical resection is the key factor for cure and should be considered the gold standard at any stage. Especially for more aggressive lesions, surgery should be considered with a multimodality approach, involving induction and adjuvant therapy according to the stage. Multimodality therapy protocols have been designed based on the integration of clinical staging and histology. Neoadjuvant therapy is now administered before surgical resection in patients with tumors considered inoperable as it improves resectability and survival and reduces the risk of recurrence. Adjuvant treatment has been extensively reported after both complete or partial resection. New targeted therapies are in the developmental stage, and in the future they will be part of the standard protocols. Integrated treatment modalities require strict cooperation between medical and radiation oncologists, thoracic surgeons, and pathologists.

show abstract

Section: Targeted Therapiesmentioning

confidence: 99%

“…91 Three observations of heavily pretreated recurrent thymomas showing a partial response to cetuximab alone have been reported. 90 The recent identifi cation of HRAS/KRAS mutations predicting primary resistance to anti-EGFR drugs 92 has to be integrated in trials evaluating cetuximab to avoid false-negative results.…”

Section: Targeted Therapiesmentioning

confidence: 99%

Thymoma and thymic carcinoma

Venuta

Rendina

Anile

et al. 2012

Gen Thorac Cardiovasc Surg

View full text Add to dashboard Cite

show abstract

“…In the case presented here, cetuximab was indeed very well tolerated and managed to delay disease progression for about 8 months. This case adds to the existing growing body of literature (8)(9) and encourages further research in this direction. At the present time, a phase II trial is undergoing evaluating neoadjuvant cetuximab plus chemotherapy in inoperable thymic tumors, with a target accrual of28 patients and primary end-point set to be the rate of complete responses to treatment (10).…”

Section: Discussionmentioning

confidence: 53%

Is Hypogammaglobulinemia a Constant Feature in Good's Syndrome?

Federico

Imbimbo

Buonerba

et al. 2010

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Thymomas are rare tumors, which can be associated to a variety of paraneoplastic syndromes, including a fatal hypogammaglobulinemia, namely Good's Syndrome (GS). Although the combination of thymoma and hypogammaglobulinemia is regarded as sufficient for diagnosis of Good's syndrome, some thymoma patients with a clear clinical picture of immunodeficiency present normal levels of immunoglobulins. We describe the case of a patient, with a 20-year history of thymoma, who underwent several operations and lines of chemotherapy, and suffered from recurrent infections, including one rare skin infection from Pseudoallescheria boydii. The patient constantly presented normal levels of gammaglobulins.

show abstract

“…One partial response of 14.8 months duration and 14 stable diseases were obtained. A case of response to cetuximab, a monoclonal antibody anti-EGFR, in a patient with pre-treated thymoma was also reported [41].…”

Section: Second-line Treatment and Novel Agentsmentioning

confidence: 97%

Chemotherapy in the treatment of thymic tumors

Tiseo

Ardizzoni

2008

Oncol Rev

View full text Add to dashboard Cite

Thymic tumors, including thymoma and thymic carcinoma, are mainly treated with surgical resection. The majority of patients with thymic tumors present with early stage and are cured with surgical excision with or without post-operative radiation. For the patients who present with unresectable stage III or IV disease, or for the patients who experience recurrence, chemotherapy can play a significant role in ensuring long-term survival and offering palliation. Thymic tumors are chemo-sensitive with optimal responses achieved with cisplatin-based combinations. A multimodality approach including chemotherapy and post-operative radiation can improve complete resection rates and longterm outcomes in locally advanced tumors. Patients with disseminated thymic tumors can have significant disease response and symptom palliation when treated with chemotherapy. Durable responses can be obtained both in metastatic and recurrent settings. Second-line treatments are available and novel therapies are currently being explored. This review provides an update of available evidence about the treatment of thymic tumors with chemotherapy.

show abstract

Response of thymoma to cetuximab

Cited by 71 publications

References 8 publications

Thymoma and thymic carcinoma

Thymoma and thymic carcinoma

Is Hypogammaglobulinemia a Constant Feature in Good's Syndrome?

Chemotherapy in the treatment of thymic tumors

Contact Info

Product

Resources

About